<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<style type="text/css">
.txt { white-space:nowrap; }
#f0 { font-family:sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff0; src: url("0.ttf"); }
#f1 { font-family:ff0,sans-serif; font-weight:bold; font-style:normal; }
@font-face { font-family: ff1; src: url("1.ttf"); }
#f2 { font-family:ff1,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff2; src: url("2.ttf"); }
#f3 { font-family:ff2,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff3; src: url("3.ttf"); }
#f4 { font-family:ff3,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff4; src: url("4.ttf"); }
#f5 { font-family:ff4,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff5; src: url("5.ttf"); }
#f6 { font-family:ff5,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff6; src: url("6.ttf"); }
#f7 { font-family:ff6,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff7; src: url("7.ttf"); }
#f8 { font-family:ff7,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff8; src: url("8.ttf"); }
#f9 { font-family:ff8,serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff9; src: url("9.ttf"); }
#f10 { font-family:ff9,monospace; font-weight:bold; font-style:normal; }
@font-face { font-family: ff10; src: url("10.ttf"); }
#f11 { font-family:ff10,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff11; src: url("11.ttf"); }
#f12 { font-family:ff11,sans-serif; font-weight:normal; font-style:normal; }
</style>
</head>
<body>
<img id="background" style="position:absolute; left:0px; top:0px;" width="595" height="842" src="page1.png">
<div class="txt" style="position:absolute; left:478px; top:72px;"><span id="f2" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">기업 </span><span id="f1" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">Note</span></div>
<div class="txt" style="position:absolute; left:497px; top:92px;"><span id="f1" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2017.11.3</span></div>
<div class="txt" style="position:absolute; left:190px; top:161px;"><span id="f11" style="font-size:20px;vertical-align:baseline;color:rgba(0,160,198,1);">한미약품(128940)</span></div>
<div class="txt" style="position:absolute; left:28px; top:192px;"><span id="f2" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">매수(상향)</span></div>
<div class="txt" style="position:absolute; left:190px; top:193px;"><span id="f12" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">체질개선과 불확실성 해소가 한번에!</span></div>
<div class="txt" style="position:absolute; left:28px; top:223px;"><span id="f2" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">목표주가: 570,000원</span></div>
<div class="txt" style="position:absolute; left:28px; top:252px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">Stock Data</span></div>
<div class="txt" style="position:absolute; left:28px; top:267px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">KOSPI(11/2)</span></div>
<div class="txt" style="position:absolute; left:157px; top:267px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">2,546</span></div>
<div class="txt" style="position:absolute; left:28px; top:278px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주가(11/2)</span></div>
<div class="txt" style="position:absolute; left:149px; top:278px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">485,000</span></div>
<div class="txt" style="position:absolute; left:28px; top:290px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">시가총액(십억원)</span></div>
<div class="txt" style="position:absolute; left:157px; top:290px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">5,414</span></div>
<div class="txt" style="position:absolute; left:28px; top:301px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">발행주식수(백만)</span></div>
<div class="txt" style="position:absolute; left:166px; top:301px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">11</span></div>
<div class="txt" style="position:absolute; left:28px; top:313px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">52주 최고/최저가(원)</span></div>
<div class="txt" style="position:absolute; left:123px; top:313px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">515,000/266,043</span></div>
<div class="txt" style="position:absolute; left:28px; top:324px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">일평균거래대금(6개월, 백만원)</span></div>
<div class="txt" style="position:absolute; left:153px; top:324px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">48,031</span></div>
<div class="txt" style="position:absolute; left:28px; top:335px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">유동주식비율/외국인지분율(%)</span></div>
<div class="txt" style="position:absolute; left:145px; top:335px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">58.2/11.3</span></div>
<div class="txt" style="position:absolute; left:28px; top:347px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주요주주(%) 한미사이언스 외 3 인</span></div>
<div class="txt" style="position:absolute; left:160px; top:347px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">41.4</span></div>
<div class="txt" style="position:absolute; left:77px; top:358px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">신동국 외 1 인</span></div>
<div class="txt" style="position:absolute; left:164px; top:358px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">9.1</span></div>
<div class="txt" style="position:absolute; left:28px; top:377px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">주가상승률</span></div>
<div class="txt" style="position:absolute; left:28px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">절대주가(%)</span></div>
<div class="txt" style="position:absolute; left:28px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">상대주가(%p)</span></div>
<div class="txt" style="position:absolute; left:92px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">1개월</span></div>
<div class="txt" style="position:absolute; left:99px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">6.7</span></div>
<div class="txt" style="position:absolute; left:99px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">0.4</span></div>
<div class="txt" style="position:absolute; left:125px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">6개월</span></div>
<div class="txt" style="position:absolute; left:128px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">57.0</span></div>
<div class="txt" style="position:absolute; left:128px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">42.2</span></div>
<div class="txt" style="position:absolute; left:154px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">12개월</span></div>
<div class="txt" style="position:absolute; left:160px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">55.5</span></div>
<div class="txt" style="position:absolute; left:160px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">26.8</span></div>
<div class="txt" style="position:absolute; left:28px; top:427px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">12MF PER 추이</span></div>
<div class="txt" style="position:absolute; left:46px; top:441px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">(배)</span></div>
<div class="txt" style="position:absolute; left:29px; top:453px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">140</span></div>
<div class="txt" style="position:absolute; left:74px; top:443px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">12MF PER (좌)</span></div>
<div class="txt" style="position:absolute; left:74px; top:451px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">한미약품 주가 (우)</span></div>
<div class="txt" style="position:absolute; left:139px; top:441px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">(천원)</span></div>
<div class="txt" style="position:absolute; left:166px; top:444px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">900</span></div>
<div class="txt" style="position:absolute; left:166px; top:454px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">800</span></div>
<div class="txt" style="position:absolute; left:29px; top:464px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">120</span></div>
<div class="txt" style="position:absolute; left:166px; top:463px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">700</span></div>
<div class="txt" style="position:absolute; left:29px; top:475px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">100</span></div>
<div class="txt" style="position:absolute; left:166px; top:473px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">600</span></div>
<div class="txt" style="position:absolute; left:166px; top:483px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">500</span></div>
<div class="txt" style="position:absolute; left:31px; top:487px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">80</span></div>
<div class="txt" style="position:absolute; left:166px; top:493px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">400</span></div>
<div class="txt" style="position:absolute; left:31px; top:498px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">60</span></div>
<div class="txt" style="position:absolute; left:166px; top:503px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">300</span></div>
<div class="txt" style="position:absolute; left:31px; top:509px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">40</span></div>
<div class="txt" style="position:absolute; left:166px; top:512px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">200</span></div>
<div class="txt" style="position:absolute; left:31px; top:521px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">20</span></div>
<div class="txt" style="position:absolute; left:166px; top:522px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">100</span></div>
<div class="txt" style="position:absolute; left:34px; top:532px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">0</span></div>
<div class="txt" style="position:absolute; left:166px; top:532px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">0</span></div>
<div class="txt" style="position:absolute; left:36px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Dec-14</span></div>
<div class="txt" style="position:absolute; left:76px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Dec-15</span></div>
<div class="txt" style="position:absolute; left:116px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Dec-16</span></div>
<div class="txt" style="position:absolute; left:28px; top:546px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">자료: WISEfn 컨센서스</span></div>
<div class="txt" style="position:absolute; left:189px; top:228px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">분기 실적에서 확인된 구조적인 체질개선</span></div>
<div class="txt" style="position:absolute; left:189px; top:243px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">3분기 매출액은 2,276억원(+3.6% YoY)로 우리 추정치 2,188억원에 부합했으나 영업이</span></div>
<div class="txt" style="position:absolute; left:189px; top:257px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">익은 우리 추정치 180억원(OPM +8.2%)을 크게 상회한 278억원(OPM +12.2%)을 기록했</span></div>
<div class="txt" style="position:absolute; left:189px; top:272px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">다. Genentech에 기술수출한 RAF 저해제가 임상 1b상에 진입하면서 반영된 예상치 못한</span></div>
<div class="txt" style="position:absolute; left:189px; top:286px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">마일스톤 59억원을 차치하더라도 수익성 높은 자체개발 개량신약의 판매증대와 신규 대형</span></div>
<div class="txt" style="position:absolute; left:189px; top:300px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">병원 납품에 따른 북경한미의 실적개선(매출액 540억원, +27% YoY, 영업이익 90억원,</span></div>
<div class="txt" style="position:absolute; left:189px; top:314px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">OPM +17% 달성)이 있었다. 이에 따라 3분기 마일스톤을 제외한 추정 원가율은 43%로</span></div>
<div class="txt" style="position:absolute; left:189px; top:328px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">전년 3분기의 50% 대비 개선됐다. 또한 한미약품은 4개의 자체개발 신제품을 추가로 출</span></div>
<div class="txt" style="position:absolute; left:189px; top:343px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">시했으며 북경한미도 매출볼륨 확대에 따른 수익성 개선이 이어질 것이기 때문에 이번 3</span></div>
<div class="txt" style="position:absolute; left:189px; top:357px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">분기에 나타난 호실적을 통해 구조적인 체질개선이 진행되고 있음을 확인했다. 이에 따라</span></div>
<div class="txt" style="position:absolute; left:189px; top:371px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">우리는 2017년과 2018년 영업이익 전망치를 종전 대비 각각 14%, 9% 상향했다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:399px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">Sanofi가 해소시켜준 불확실성은 랩스커버리의 신뢰도 상승으로 이어질 것</span></div>
<div class="txt" style="position:absolute; left:189px; top:414px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">11월 2일 Sanofi는 3분기 실적발표 컨퍼런스에서 한미약품과 계약한 에페글레나타이드</span></div>
<div class="txt" style="position:absolute; left:189px; top:428px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">(GLP-1 작용제)에 대한 임상 3상을 기존 계획대로 올해 4분기에 진행한다고 발표했다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:442px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">당초 2016년 4분기 임상 3상의 진행이 지연되며 임상중단에 대한 우려가 있었으나 이번</span></div>
<div class="txt" style="position:absolute; left:189px; top:456px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">발표로 이에 대한 불확실성이 해소됐다. 에페글레나타이드는 한미약품의 파이프라인 중</span></div>
<div class="txt" style="position:absolute; left:189px; top:470px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">가장 가치가 클 것으로 추정되는 중요한 품목이다. Sanofi의 이번 임상진행 결정은 한미</span></div>
<div class="txt" style="position:absolute; left:189px; top:485px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">약품의 랩스커버리에 대한 신뢰도 상승으로 이어질 전망이다. Sanofi 외에도</span></div>
<div class="txt" style="position:absolute; left:189px; top:499px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">Janssen(HM12525A), Spectrum(롤론티스) 등에 기술수출한 품목들 역시 랩스커버리 플</span></div>
<div class="txt" style="position:absolute; left:189px; top:513px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">랫폼이 적용된 품목들로 이번 Sanofi의 임상진행은 타 파이프라인의 전반적인 임상진행에</span></div>
<div class="txt" style="position:absolute; left:189px; top:527px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">도 긍정적인 영향을 미칠 수 있다는 판단이다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:555px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">언제 터질지 모르는 파이프라인에 대한 기대감</span></div>
<div class="txt" style="position:absolute; left:189px; top:570px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2018년 순이익 1,186억원에 대형 제약사 적정 target PER 23배를 적용한 본업가치 2.8</span></div>
<div class="txt" style="position:absolute; left:189px; top:584px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">조원, 신약가치 3.9조원, 순차입금 -3,316억원을 합산하여 산출한 한미약품의 목표주가</span></div>
<div class="txt" style="position:absolute; left:189px; top:598px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">는 57만원이다. 이번 목표주가 산출로 17%의 주가 상승여력이 발생함에 따라 투자의견도</span></div>
<div class="txt" style="position:absolute; left:189px; top:612px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">기존 중립에서 매수로 상향한다. 현재 한미약품은 2018년 기준 PER 46배에서 거래되고</span></div>
<div class="txt" style="position:absolute; left:189px; top:627px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">있어 valuation부담이 있으나 2018년 Spectrum, Eli Lilly, Genentech 등으로부터 마일</span></div>
<div class="txt" style="position:absolute; left:189px; top:641px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">스톤 유입이 전망됨에 따라 주가는 하방경직성을 확보하고 있다는 판단이다. 한미약품의</span></div>
<div class="txt" style="position:absolute; left:189px; top:655px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">강력한 R&amp;D능력을 감안하면 전임상 단계에 있는 기타 파이프라인들의 추가적인 기술수</span></div>
<div class="txt" style="position:absolute; left:189px; top:669px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">출도 언제든지 가능할 것으로 예상됨에 따라 장기적 관점에서 매수를 권고한다.</span></div>
<div class="txt" style="position:absolute; left:29px; top:721px;"><span id="f5" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">진홍국</span></div>
<div class="txt" style="position:absolute; left:29px; top:733px;"><span id="f3" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">hg.jin@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:29px; top:751px;"><span id="f5" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">정은영</span></div>
<div class="txt" style="position:absolute; left:29px; top:763px;"><span id="f3" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">eunice.jung@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:228px; top:694px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">매출액 영업이익 순이익</span></div>
<div class="txt" style="position:absolute; left:336px; top:694px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EPS 증감률 EBITDA PER </span><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EV/EBITDA </span><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">PBR ROE DY</span></div>
<div class="txt" style="position:absolute; left:223px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(십억원) (십억원) (십억원)</span></div>
<div class="txt" style="position:absolute; left:338px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(원) (%) (십억원)</span></div>
<div class="txt" style="position:absolute; left:424px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x)</span></div>
<div class="txt" style="position:absolute; left:453px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x)</span></div>
<div class="txt" style="position:absolute; left:478px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x) (%) (%)</span></div>
<div class="txt" style="position:absolute; left:189px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2015A</span></div>
<div class="txt" style="position:absolute; left:230px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">1,318</span></div>
<div class="txt" style="position:absolute; left:270px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">212</span></div>
<div class="txt" style="position:absolute; left:304px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">154 14,830 331.9</span></div>
<div class="txt" style="position:absolute; left:394px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">262 45.9 29.4 10.3 25.7 0.3</span></div>
<div class="txt" style="position:absolute; left:189px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2016A</span></div>
<div class="txt" style="position:absolute; left:236px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">883</span></div>
<div class="txt" style="position:absolute; left:274px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">27</span></div>
<div class="txt" style="position:absolute; left:308px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">23 2,242 (84.9)</span></div>
<div class="txt" style="position:absolute; left:398px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">66 127.4 49.3 4.5 3.5</span></div>
<div class="txt" style="position:absolute; left:534px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2017F</span></div>
<div class="txt" style="position:absolute; left:236px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">922</span></div>
<div class="txt" style="position:absolute; left:270px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">103</span></div>
<div class="txt" style="position:absolute; left:308px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">65 5,867 161.7</span></div>
<div class="txt" style="position:absolute; left:394px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">139 82.7 41.2 8.1 9.9</span></div>
<div class="txt" style="position:absolute; left:534px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2018F</span></div>
<div class="txt" style="position:absolute; left:230px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">1,055</span></div>
<div class="txt" style="position:absolute; left:270px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">149</span></div>
<div class="txt" style="position:absolute; left:304px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">119 10,670 81.9</span></div>
<div class="txt" style="position:absolute; left:394px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">196 45.5 29.8 8.7 18.6</span></div>
<div class="txt" style="position:absolute; left:534px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2019F</span></div>
<div class="txt" style="position:absolute; left:230px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">1,153</span></div>
<div class="txt" style="position:absolute; left:270px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">183</span></div>
<div class="txt" style="position:absolute; left:304px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">148 13,358 25.2</span></div>
<div class="txt" style="position:absolute; left:394px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">239 36.3 24.0 8.0 23.1</span></div>
<div class="txt" style="position:absolute; left:534px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:775px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">주: 순이익, EPS 등은 지배주주지분 기준</span></div>
</body>
</html>
